NewDrug is a privately held start up biotechnology company based in Patras Science Park (Greece) specializing in the design, synthesis and development of novel drugs for Multiple Sclerosis, Hypertension and COVID-19. With the technology to produce delivery platforms aiming to regulate the immune system of Multiple Sclerosis patients, it provides a potential therapy which eliminates the side effects of current anti-inflammatory drugs. In addition, Newdrug has the technology to design and synthesize anti-hypertensive Sartans, now proved to also be effective in the inhibition of SARS-CoV-2. NewDrug is leading an international network including top experts in chemical biology and immunology. The aim of this research is the eradication of MS disease by selectively removing disease-inducing cells from patients. NewDrug ‘s researchers possess the know-how for vaccine production in Multiple Sclerosis and the production of highly potent Sartans. They are the inventors of granted patents (U.S.A, Europe, Australia) for myelin epitope based vaccines and hypertension. They were also the first worldwide to design constraint cyclic analogues for important peptide hormones such as Angiotensin II, Gonadotropin Realizing Hormone, Myelin Epitopes, Thrombin Receptor Activating Peptides and develop delivery sugar platforms to direct myelin antigens to dendritic cell regulating the immune system. Backed by more than 30 years of research and technical expertise, NewDrug’s groundbreaking research in organic and peptide synthesis and matrix delivery technology allows cell drug delivery selectivity. NewDrug can achieve block-buster status for a global vaccine drug and Sartans mimetic drugs which can be applied in the treatment of Covid 19. Our laboratory is conducting world class research. Five Nobel laureates has visted it so far (J. Watson, H. Hausen, J.M. Lehn, A. Yonath, A. Schally). Leader of this technology is Professor John Matsoukas, at Patras Science Park, Greece.
